On September 3, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 to 15, 2021 (Press release, Phio Pharmaceuticals, SEP 3, 2021, View Source [SID1234587234]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Phio Company Presentation Details:
Speaker: Dr. Gerrit Dispersyn, President & CEO of Phio Pharmaceuticals
Time/Date: Available starting at 7:00 AM ET on Monday, September 13th
Webcast: Registration (Click Here)
Replay: Interested parties may also access a replay of the Company presentation through the "Investors – Events and Presentations" section of the Company’s website (click here). The webcast will be archived and available on the Company’s website for 90 days.
For more information on the conference, or to schedule a one-on-one meeting, please contact a H.C. Wainwright representative.